Longeveron (LGVN) Total Liabilities (2020 - 2026)
Longeveron (LGVN) recorded quarterly Total Liabilities of $5.2 million in Q1 2026, up 13.02% quarter-over-quarter from $4.6 million in Q4 2025, and up 40.46% on a YoY basis from $3.7 million in Q1 2025.
Longeveron (LGVN) Total Liabilities (2020 - 2026) Analysis & Trends
Longeveron's Total Liabilities history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 40.46% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (up 40.46% YoY), while the FY2025 annual figure was $4.6 million, up 24.93% from the prior year.
- Total Liabilities was $5.2 million for Q1 2026 at Longeveron, up from $4.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $6.9 million in Q4 2022 to a low of -$34.3 million in Q1 2022.
- Historically, Total Liabilities has averaged -$1.0 million across 5 years, with a median of $4.6 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 120.28% in 2023, then slumped 44.56% in 2025.
- A 5-year view of Total Liabilities shows it stood at $6.9 million in 2022, then dropped by 22.76% to $5.3 million in 2023, then plunged by 31.22% to $3.7 million in 2024, then grew by 24.93% to $4.6 million in 2025, then grew by 13.02% to $5.2 million in 2026.
- The last three Total Liabilities figures came in at $5.2 million (Q1 2026), $4.6 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 10.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 19.51 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 137.56 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.18 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 4.09 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Mar 31, 2024 | 6.66 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Sep 30, 2023 | 4.99 Mn |
| Jun 30, 2023 | 5.83 Mn |
| Mar 31, 2023 | 5.49 Mn |
| Dec 31, 2022 | 6.91 Mn |
| Sep 30, 2022 | -24.62 Mn |
| Jun 30, 2022 | -29.38 Mn |
| Mar 31, 2022 | -34.31 Mn |
| Dec 31, 2021 | 5.31 Mn |
| Dec 31, 2020 | -1.96 Mn |